Next-generation prevention tools, including long-acting monoclonal antibodies (mAbs), offer potential to reduce respiratory illnesses such as RSV. However, existing immunization policies and delivery models are not always well-suited to these innovations, particularly where classification and financing pathways diverge from those used for traditional vaccines. This project addresses these challenges through a structured, multi-pronged approach. At the system level, it will develop an adaptable regional framework to help economies strengthen readiness for new prevention tools. At the applied level, it will use pediatric RSV mAbs as a case study to generate practical insights on regulatory alignment, financing, and delivery. An interactive dashboard will complement the framework, enabling ongoing progress.

Designed to be product-agnostic and adaptable across diverse contexts, the framework—supported by the dashboard—will enable cross-economy learning and locally tailored introduction strategies. These outputs will be launched to support more resilient, equitable immunization systems and maximize public health impact.